Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model

Mamoudou Maiga; Nisheeth Agarwal; Nicole C. Ammerman; Radhika Gupta; Haidan Guo; Marama C. Maiga; Shichun Lun; William R. Bishai

doi:10.1371/journal.pone.0030749

Loading metrics

Open Access

Peer-reviewed

Research Article

Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model

Mamoudou Maiga ,

Contributed equally to this work with: Mamoudou Maiga, Nisheeth Agarwal

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
⨯
Nisheeth Agarwal ,

Contributed equally to this work with: Mamoudou Maiga, Nisheeth Agarwal

Affiliations Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Gurgaon, India
⨯
Nicole C. Ammerman,

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
⨯
Radhika Gupta,

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
⨯
Haidan Guo,

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
⨯
Marama C. Maiga,

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
⨯
Shichun Lun,

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
⨯
William R. Bishai

* E-mail: wbishai1@jhmi.edu

Affiliations Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America
⨯

Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model

Mamoudou Maiga,
Nisheeth Agarwal,
Nicole C. Ammerman,
Radhika Gupta,
Haidan Guo,
Marama C. Maiga,
Shichun Lun,
William R. Bishai

Published: February 3, 2012
https://doi.org/10.1371/journal.pone.0030749

About the Authors

Mamoudou Maiga

Contributed equally to this work with: Mamoudou Maiga, Nisheeth Agarwal

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

Nisheeth Agarwal

Contributed equally to this work with: Mamoudou Maiga, Nisheeth Agarwal

Affiliations Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Gurgaon, India

Nicole C. Ammerman

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

Radhika Gupta

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

Haidan Guo

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

Marama C. Maiga

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

Shichun Lun

Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

William R. Bishai

* E-mail: wbishai1@jhmi.edu

Affiliations Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: MM NA NCA RG SL WRB. Performed the experiments: MM NA NCA RG HG MCM. Analyzed the data: MM NA NCA RG WRB. Contributed reagents/materials/analysis tools: WRB. Wrote the paper: MM NA NCA WRB.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Tuberculosis
Is the Subject Area "Tuberculosis" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Mycobacterium tuberculosis
Is the Subject Area "Mycobacterium tuberculosis" applicable to this article?

Thanks for your feedback.
Chemotherapy
Is the Subject Area "Chemotherapy" applicable to this article?

Thanks for your feedback.
Aerosols
Is the Subject Area "Aerosols" applicable to this article?

Thanks for your feedback.
Extensively drug-resistant tuberculosis
Is the Subject Area "Extensively drug-resistant tuberculosis" applicable to this article?

Thanks for your feedback.